Cargando…
Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
CONTEXT: Coronary artery disease (CAD) is among the leading causes of mortality and morbidity worldwide. Traditional risk markers explain only a proportion of total cardiovascular risk. Thus, development and improvement of early diagnostic strategies and targeted initiation of preventive measures wo...
Autores principales: | Tarasov, Kirill, Ekroos, Kim, Suoniemi, Matti, Kauhanen, Dimple, Sylvänne, Tuulia, Hurme, Reini, Gouni-Berthold, Ioanna, Berthold, Heiner K., Kleber, Marcus E., Laaksonen, Reijo, März, Winfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928964/ https://www.ncbi.nlm.nih.gov/pubmed/24243630 http://dx.doi.org/10.1210/jc.2013-2559 |
Ejemplares similares
-
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013) -
Lipidomics: A Tool for Studies of Atherosclerosis
por: Ekroos, Kim, et al.
Publicado: (2010) -
Shotgun Lipidomics by Sequential Precursor Ion Fragmentation on a Hybrid Quadrupole Time-of-Flight Mass Spectrometer
por: Simons, Brigitte, et al.
Publicado: (2012) -
Effects of immunization against PCSK9 in an experimental model of breast cancer
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2019) -
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)